Company Overview - Yifang Biotechnology (Shanghai) Co., Ltd. is a research-driven biopharmaceutical company based in China, focusing on significant unmet medical needs in oncology, autoimmune diseases, and metabolic disorders [5] - The company has established a comprehensive and differentiated product pipeline, including two commercialized products (BPI-D0316 and D-1553), two core clinical-stage products (D-2570 and D-0502), one clinical-stage candidate (D-0120), and three preclinical candidates (YF087, YF550, and YF057) [5][6] - BPI-D0316, a third-generation EGFR inhibitor, and D-1553, a KRAS G12C inhibitor, have been approved for marketing in China and included in the National Reimbursement Drug List (NRDL) [5][6] Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenues of approximately RMB 168.79 million, with a gross profit of RMB 164.77 million [8][9] - The company recorded a net loss of approximately RMB 240.20 million for the same period [10] - As of September 30, 2025, the company achieved revenues of approximately RMB 30.89 million, with a gross profit of RMB 26.74 million, and a net loss of approximately RMB 181.39 million [8][10] Customer Dependency - The company has a high customer dependency, with revenues from its largest customer accounting for 90.3% and 73.6% of total revenues for the fiscal years ending December 31, 2024, and September 30, 2025, respectively [7] Industry Overview - The global oncology drug market is projected to grow from USD 143.5 billion in 2019 to USD 253.3 billion by 2024, with a compound annual growth rate (CAGR) of 12.0%, and expected to reach USD 702.7 billion by 2035 [12] - The Chinese oncology drug market is expected to grow from USD 26.5 billion in 2019 to USD 35.9 billion by 2024, with a CAGR of 6.3%, and projected to reach USD 145 billion by 2035 [12] - The global targeted oncology drug market is anticipated to grow from USD 85.5 billion in 2019 to USD 154 billion by 2024, with a CAGR of 12.5%, and expected to reach USD 320.5 billion by 2035 [14] - The Chinese targeted oncology drug market is expected to grow from USD 6.2 billion in 2019 to USD 16.6 billion by 2024, with a CAGR of 21.8%, and projected to reach USD 61.6 billion by 2035 [14]

Company Overview - Junshi Biosciences has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on innovative cell therapies and drug development for solid tumors, aiming to create safer, more effective, accessible, and affordable immunotherapy solutions [1] Core Product - The core product, GC101, is the world's first tumor-infiltrating lymphocyte (TIL) therapy that does not require high-intensity lymphodepleting chemotherapy or IL-2 administration, potentially becoming the first TIL therapy approved for market in China [1] - Clinical data indicates that TIL therapy can provide curative effects for some late-stage cancer patients, showing long-term benefits for patients with advanced melanoma, non-small cell lung cancer, and breast cancer [1] Clinical Trials - Phase I clinical trials for TIL therapy have demonstrated objective response rates in various advanced metastatic solid tumors, including melanoma, non-small cell lung cancer, and cervical cancer [1] Therapy Characteristics - TIL therapy is a personalized treatment with breakthrough efficacy; however, its complex preparation process and clinical protocols lead to high costs and limited accessibility, restricting widespread application [1] - The company aims to innovate from production to clinical application to enhance the safety, accessibility, and affordability of TIL therapy while maintaining its curative potential [1] Industry Growth - The global oncology drug market is projected to grow to $253.3 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% from 2020 to 2024 [2] - By 2030, the market is expected to expand to $452.5 billion, with a CAGR of 10.2% from 2024 to 2030, and reach $702.7 billion by 2035, with a CAGR of 9.2% from 2030 to 2035 [2] - In China, the oncology drug market is anticipated to reach RMB 258.2 billion in 2024, with a CAGR of 6.9% from 2020 to 2024, and is expected to accelerate to RMB 527.3 billion by 2030 [2]

Core Viewpoint - The company, Huayi Family, is responding to a regulatory inquiry regarding its acquisition of Haihe Pharmaceuticals, which is focused on innovative cancer drugs. The inquiry raises questions about the necessity of the transaction given the financial performance of both companies, particularly the losses incurred by Haihe Pharmaceuticals and the strategic rationale behind the acquisition [1][20]. Group 1: Industry Overview - The oncology drug market is experiencing significant growth, with global cancer incidence rising from 18.52 million in 2019 to 20.78 million in 2023, reflecting a compound annual growth rate (CAGR) of 2.9%. Projections indicate that by 2030, the number of new cancer cases could reach approximately 24.46 million [2]. - In China, the number of new cancer cases is also on the rise, reaching 4.93 million in 2023, with an expected increase to 5.65 million by 2030, representing a CAGR of 2.0% from 2026 to 2030 [3]. - The global oncology drug market grew from $129 billion in 2018 to $223.2 billion in 2023, with a CAGR of 11.6%. The Chinese oncology drug market increased from $19.9 billion to $30.9 billion during the same period, with a CAGR of 9.2% [4]. Group 2: Haihe Pharmaceuticals Overview - Haihe Pharmaceuticals specializes in the research and development of small molecule anti-cancer drugs, with a pipeline that includes over ten research projects. Three products have been commercialized in China and Japan, while five are in clinical research [4][10]. - The company's main products include SCC244 (Gumetinib) and RMX3001 (oral paclitaxel), with SCC244 approved for treating advanced non-small cell lung cancer (NSCLC) with c-Met exon 14 mutations. RMX3001 is the only approved oral paclitaxel product globally, targeting gastric cancer and showing significant patient compliance advantages [5][6][10]. - Haihe's products demonstrate competitive advantages in clinical efficacy, pharmacological characteristics, and safety profiles compared to similar products in the market [5][10]. Group 3: Financial Performance and Strategic Rationale - Haihe Pharmaceuticals reported revenues of CNY 323 million and CNY 76.82 million for 2024 and the first two months of 2025, respectively, but incurred net losses of CNY 209 million and CNY 16.08 million during the same periods [1]. - Huayi Family's main business is real estate development, with revenues of CNY 161 million and CNY 353 million for 2023 and 2024, respectively, and a projected net loss of CNY 12.5 million to CNY 8.35 million for the first half of 2025 [1][14]. - The acquisition of Haihe Pharmaceuticals is seen as a strategic move to diversify Huayi Family's business and tap into the growing biopharmaceutical sector, which is supported by national policies aimed at fostering innovation in drug development [17][20].